# Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates

> **NCT05064488** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Evobrutinib (45mg)
- **DRUG:** Digoxin (0.25mg)
- **DRUG:** Metformin (10mg)
- **DRUG:** Rosuvastatin (10mg)
- **DRUG:** Sumatriptan (25mg)

## Key facts

- **NCT ID:** NCT05064488
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-04
- **Primary completion:** 2021-12-10
- **Final completion:** 2021-12-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05064488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05064488, "Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05064488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*